Loading…
Legislative Progress
Introduced
December 11, 2014
Latest Action
December 11, 2014
Primary Sponsor
Orrin G. HatchRepublican(UT)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,002 other S bills in the 113th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · third_quarter · Health Issues
Interoperability and Regulation of Health IT, including the SOFTWARE Act (H.R. 2396), MEDTECH Act (S. 1101), Improving Heath Information Technology Act (S. 3511), and 21st Century Cures Act (H.R. 6). Food and Drug Administration: drug, medical device, and agency reforms including improving scientific capacity at FDA and use of public-private partnerships (FDA and NIH Workforce Authorities Modernization Act, S. 2700); use of real-world evidence and drug development tools such as biomarkers and patient-reported outcomes (21st Century Cures Act, H.R. 6); and the approval process for certain items such as antibiotics (e.g., PATH Act, S. 185), treatments for unmet needs (e.g., Dormant Therapies Act of 2014, S. 3004, 113th Congress), combination products (e.g., S. 1767), and regenerative medicine/cellular therapies (REGROW Act, S. 2689/H.R. 4762). Medicare, including chronic care coordination, prevention, and health care delivery and payment reform Long-term care financing and Medicaid Money Follows the Person Rebalancing Demonstration program reauthorization Beneficiaries dually eligible for Medicare and Medicaid
Client expense: $260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Interoperability and Regulation of Health IT, including the SOFTWARE Act (H.R. 2396), MEDTECH Act (S. 1101), and 21st Century Cures Act (H.R. 6). Food and Drug Administration: drug, medical device, and agency reforms including improving scientific capacity at FDA and use of public-private partnerships (FDA and NIH Workforce Authorities Modernization Act, S. 2700); use of real-world evidence and drug development tools such as biomarkers and patient-reported outcomes (21st Century Cures Act, H.R. 6); and the approval process for certain items such as antibiotics (e.g., PATH Act, S. 185), treatments for unmet needs (e.g., Dormant Therapies Act of 2014, S. 3004, 113th Congress), combination products (e.g., S. 1767), and regenerative medicine/cellular therapies (REGROW Act, S. 2689/H.R. 4762). Medicare, including chronic care coordination, prevention, and health care delivery and payment reform Long-term care financing Beneficiaries dually eligible for Medicare and Medicaid
Client expense: $351,424 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Interoperability and Regulation of Health IT, including the SOFTWARE Act (H.R. 2396), MEDTECH Act (S. 1101), and 21st Century Cures Act (H.R. 6). Food and Drug Administration: drug, medical device, and agency reforms including improving scientific capacity at FDA and use of public-private partnerships (FDA and NIH Workforce Authorities Modernization Act, S. 2700); use of real-world evidence and drug development tools such as biomarkers and patient-reported outcomes (21st Century Cures Act, H.R. 6); and the approval process for certain items such as antibiotics (e.g., PATH Act, S. 185), treatments for unmet needs (e.g., Dormant Therapies Act of 2014, S. 3004, 113th Congress), combination products (e.g., S. 1767), and regenerative medicine/cellular therapies (REGROW Act, S. 2689/H.R. 4762). Medicare, including chronic care coordination, prevention, and health care delivery and payment reform. Long-term care fiancing Beneficiaries dually eligible for Medicare and Medicaid Child Nutrition Reauthorization
Client expense: $366,288 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Interoperability and Regulation of Health IT, including the SOFTWARE Act (H.R. 2396), MEDTECH Act (S. 1101), and 21st Century Cures Act (H.R. 6). Food and Drug Administration: drug, medical device, and agency reforms including improving scientific capacity at FDA and use of public-private partnerships; use of real-world evidence and drug development tools such as biomarkers and patient-reported outcomes (21st Century Cures Act, H.R. 6); and the approval process for certain items such as antibiotics (e.g., PATH Act, S. 185), treatments for unmet needs (e.g., Dormant Therapies Act of 2014, S. 3004, 113th Congress), combination products (e.g., S. 1767), and regenerative medicine/cellular therapies. Medicare, including chronic care coordination, prevention, and health care delivery and payment reform Beneficiaries dually eligible for Medicare and Medicaid Child Nutrition Reauthorization
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Copyright/Patent/Trademark
H.R. 3116, MODDERN Cures Act of 2013; S. 3004, Dormant Therapies Act of 2014; H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; H.R. 1537 & S. 1878, Advancing Hope Act of 2015; S. 1720, Patent Transparency and Improvements Act of 2013; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; H.R. 160, Protect Medical Innovation Act of 2015; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; Proposals/Initiatives related to international intellectual property protection;
Client expense: $1,180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2015 · third_quarter · Health Issues
Interoperability and Regulation of Health IT, including the SOFTWARE Act (H.R. 2396), MEDTECH Act (S. 1101), and 21st Century Cures Act (H.R. 6). Food and Drug Administration: drug, medical device, and agency reforms including improving scientific capacity at FDA and use of public-private partnerships; use of real-world evidence and drug development tools such as biomarkers and patient-reported outcomes (21st Century Cures Act, H.R 6); and the approval process for certain items such as antibiotics (e.g., PATH Act, S. 185), treatments for unmet needs (e.g., Dormant Therapies Act of 2014, S. 3004, 113th Congress), combination products (e.g., S. 1767), and regenerative medicine/cellular therapies. Medicare, including chronic care coordination, prevention, and health care delivery and payment reform Beneficiaries dually eligible for Medicare and Medicaid
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Copyright/Patent/Trademark
H.R. 3116, MODDERN Cures Act of 2013; S. 3004, Dormant Therapies Act of 2014; H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; H.R. 1537 & S. 1878, Advancing Hope Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; Proposals/Initiatives related to international intellectual property protection;
Client expense: $1,240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2014 · fourth_quarter · Health Issues
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B Issues Drug Shortage Issues Health Technology Assessment of Orphan DrugsH.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2013 S. 1417, Newborn Screening Saves Lives Reauthorization Act of 2013 Sequestration of FDA User Fees H.R. 2315, Preserving Access to Orphan Drugs Act of 2013 S. 1128, Preserving Access to Orphan Drugs Act of 2013 H.R. 2090, Patient Choice Act of 2013 H.R. 4475, Compassionate Freedom of Choice Act of 2014 H.R. 1239, Accessing Medicare Therapies Act of 2013 H.R. 460, Patients' Access to Treatments Act of 2013 21st Century Cures Initiatives H.R. 3805, Andrea Sloan CURE Act H.R. 3116, MODDERN Cures Act of 2013 S. 3004, Dormant Therapies Act of 2014 H.R. 5771, To amend the Internal Revenue Code of 1986 to extend certain expiring provisions and make technical corrections, to amend the Internal Revenue Code of 1986 to provide for the tax treatment of ABLE accounts established under State programs for the care of family members with disabilities, and for other purposes. H.R. 5750, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014
Client expense: $370,000 · Firm income: Not reported
2014 · fourth_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Client expense: $750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Copyright/Patent/Trademark
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Copyright/Patent/Trademark
H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2639, Patent Litigation and Innovation Act: Patent litigation provisions H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets H.R. 5750, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014: Provisions related to targeted IP incentives for new indications for rare diseases or conditions S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act: Patent litigation provisions S. 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets S. 3004, Dormant Therapies Act of 2014: Provisions related to incentives to develop biopharmaceutical products Biopharmaceutical innovation and patent policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property
2014 · fourth_quarter · Health Issues
H.R. 4299, The Improving Regulatory Transparency for New Medical Therapies Act; H.R. 3077, TELE-MED Act of 2013; H.R. 460, Patient Access to Treatments Act; S. 2862, The Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act; S.3004 The Dormant Therapies Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
HR 3116: MODDERN Cures Act S 3004: Dormant Therapies Act Affordable Care Act Implementation -out of pocket costs -plan oversight -transparency and enrollment -Physician Payment Sunshine Act 21st Century Cures
Client expense: $6,240 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $3,960,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Medicare Payment Advisory Commission (MedPAC), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)